Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Wollenberg, Andreas ^{[2
]}

Pink, Andrew ^{[3
]}

Peris, Ketty ^{[4
,5
]}

Gemelli, A.

Armstrong, April ^{[6
]}

Spelman, Lynda ^{[7
]}

Saeki, Hidehisa ^{[8
]}

Lynde, Charles ^{[9
,10
]}

Herranz, Pedro ^{[11
]}

Barbarot, Sebastien ^{[12
]}

Simpson, Eric ^{[13
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Ludwig Maximilian Univ Munich, Dept Dermatol & Allergol, Munich, Germany

[3] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England

[4] Catholic Univ, Dermatol, Milan, Italy

[5] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

[6] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA

[7] Verac Clin Res, Woolloongabba, Qld, Australia

[8] Nippon Med Sch, Dept Dermatol, Tokyo, Japan

[9] Univ Toronto, Prob Med Res, Lynde Dermatol, Toronto, ON, Canada

[10] Univ Toronto, Dept Med, Toronto, ON, Canada

[11] Hosp Univ La Paz, Dept Dermatol, Madrid, Spain

[12] CHU Nantes, Nantes, France

[13] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

28171

引用

页码：AB177 / AB177

页数：1

共 50 条

[21] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
Zhao Yan
Zhang Jianzhong
Yang Bin
Li Jingyi
Ding Yangfeng
Wu Liming
Zhang Litao
Wang Jinyan
Zhu Xiaohong
Zhang Furen
Tao Xiaohua
Li Yumei
Zhang Chunlei
Li Linfeng
Lu Jianyun
Diao Qingchun
Lu Qianjin
Man Xiaoyong
Li Fuqiu
Xia Xiujuan
Cheng Hao
Jia Yingmin
Zhao Guoqing
Yan Jinchun
Chen Bo
中华医学杂志英文版, 2024, 137 (02)
[22] Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
Katoh, Norito
Tanaka, Akio
Takahashi, Hidetoshi
Shimizu, Ryosuke
Kataoka, Yoko
Torisu-Itakura, Hitoe
Morisaki, Yoji
Igawa, Ken
CURRENT MEDICAL RESEARCH AND OPINION, 2025, 41 (01) : 1 - 12
[23] Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study
Cai, L.
Gu, J.
Zheng, J.
Zheng, M.
Wang, G.
Xi, L. -Y.
Hao, F.
Liu, X. -M.
Sun, Q. -N.
Wang, Y.
Lai, W.
Fang, H.
Tu, Y. -T.
Sun, Q.
Chen, J.
Gao, X. -H.
Gu, Y.
Teixeira, H. D.
Zhang, J. -Z.
Okun, M. M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 89 - 95
[24] Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial
Merola, Joseph F.
Parish, Lawrence Charles
Guenther, Lyn
Lynde, Charles
Lacour, Jean -Philippe
Staubach, Petra
Cheng, Sue
Paris, Maria
Picard, Hernan
Deignan, Cynthia
Jardon, Shauna
Chen, Mindy
Papp, Kim A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (03) : 485 - 493
[25] Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials
Mendes-Bastos, Pedro
Ladizinski, Barry
Guttman-Yassky, Emma
Jiang, Ping
Liu, John
Prajapati, Vimal H.
Simpson, Eric L.
Vigna, Namita
Teixeira, Henrique D.
Barbarot, Sebastien
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 784 - 791
[26] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Serra-Baldrich, Esther
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Gil, Esther Garcia
Silverberg, Jonathan, I
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 740 - 748
[27] Tralokinumab significantly reduces Staphylococcus aureus colonization in adult patients with moderate-to-severe atopic dermatitis (AD): Results from a Phase 2b, randomized, double-blind, placebo-controlled study (NCT02347176)
Guttman-Yassky, E.
Silverberg, J. I.
Fensholdt, J.
Lindegaard, K. K.
Wollenberg, A.
EXPERIMENTAL DERMATOLOGY, 2018, 27 : 41 - 41
[28] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
Blauvelt, Andrew
Gooderham, Melinda
Bhatia, Neal
Langley, Richard G.
Schneider, Shannon
Zoidis, John
Kurbasic, Azra
Armstrong, April
Silverberg, Jonathan, I
DERMATOLOGY AND THERAPY, 2022, 12 (11) : 2499 - 2516
[29] Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis:: a randomized, double-blind, placebo-controlled trial
Berth-Jones, J.
Arkwright, P. D.
Marasovic, D.
Savani, N.
Aldridge, C. R.
Leech, S. N.
Morgan, C.
Clark, S. M.
Ogilvie, S.
Chopra, S.
Harper, J. I.
Smith, C. H.
Rook, G. A. W.
Friedmann, P. S.
CLINICAL AND EXPERIMENTAL ALLERGY, 2006, 36 (09): : 1115 - 1121
[30] Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
Andrew Blauvelt
Melinda Gooderham
Neal Bhatia
Richard G. Langley
Shannon Schneider
John Zoidis
Azra Kurbasic
April Armstrong
Jonathan I. Silverberg
Dermatology and Therapy, 2022, 12 : 2499 - 2516

← 1 2 3 4 5 →